Have you read the financials?
In the last 10-Q the revenue is only $1,571.
How is it that a pharmaceutical company only spends $68,172 on R&D for the quarter.
For the 9 months ending on May 31, 2017 we find:
"Net cash provided by financing activities = $3,782,356"
The we find:
"Proceeds from sale of common stock = $3,858,980"
"On January 5, 2017, the Company issued 5,055,334 shares to 13 investors at $.09 per share for a total of $449,573. Also on January 5, 2017, the Company issued 1,800,000 shares to 7 individuals who exercised their previous Warrant Rights at $.03 per share for a total of $54,000."
The company is being very generous to insiders.
I also noticed in the Assets that the company doesn't have any IP listed as a asset on the Balance Sheet.
IG
News 
Market Data 
Discover 
